(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060862 A3

(51) International Patent Classification[7]: C07D 207/16, 295/18, A61K 31/401, 31/4025, 31/40

(21) International Application Number:
PCT/FI2004/000001

(22) International Filing Date: 2 January 2004 (02.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20030014 3 January 2003 (03.01.2003) FI

(71) Applicant *(for all designated States except US)*: **ORION CORPORATION** [FI/FI]; Orionintie 1, FIN-02200 Espoo (FI).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GYNTHER, Jukka** [FI/FI]; Juho Rissasenkatu 17, FIN-70500 Kuopio (FI). **WALLÉN, Erik** [FI/FI]; Vuorikatu 4 A 16, FIN-70100 (FI). **JARHO, Elina** [FI/FI]; Hiihtäjäntie 15 G 46, FIN-70200 (FI). **MÄNNISTÖ, Pekka** [FI/FI]; Abrahaminkatu 9 B 37, FIN-00180 Helsinki (FI). **FORSBERG, Markus** [FI/FI]; Varsitie 13 C 12, FIN-70150 Kuopio (FI). **POSO, Antti** [FI/FI]; Vehnäkuja 3, FIN-76150 Pieksämäki (FI). **CHRISTIAANS, Johannes** [NL/NL]; Zevenwouden 233, NL-3524 CR Utrecht (NL). **VENÄLÄINEN, Jarkko** [FI/FI]; Taivaanpankontie 17 B 15, FIN-70200 Kuopio (FI). **VEPSÄLÄINEN, Jouko** [FI/FI]; Korpitie 24, FIN-70780 Kuopio (FI). **SAARINEN, Taija** [FI/FI]; Hatsalankatu 36 A 2, FIN-70110 Kuopio (FI). **JÄRVINEN, Tomi** [FI/FI]; Sompatie 3 I 6, FIN-70200 Kuopio (FI).

(74) Agent: **ORION CORPORATION**; Orion Pharma, Legal Affairs and Intellectual Property Rights, P.O. Box 65, Fin-02101 Espoo (FI).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
25 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY



(I)

(57) Abstract: The invention provides a compound of formula (I), wherein in the formula X, R_1, R_2 and R_3 are as defined in claim 1, or a pharmaceutically acceptable salt or ester thereof, useful as a prolyl oligopeptidase inhibitor. The compounds of formula (I) can be used for the treatment of diseases or conditions where prolyl oligopeptidase inhibitors are indicated to be effective, for example for the treatment of neurodegenerative diseases, such as Alzheimer's disease and senile dementia

WO 2004/060862 A3